🔗 Share this article

An underground market for unlicensed weight-loss drugs is propelled by social media fitness personalities and vendors on communication apps, according to new investigations.

Investigational Drug Gaining Popularity Via Social Media

Retatrutide, which is still in clinical trials, is being advertised by social media influencers for its alleged weight-reducing properties. Viewers are encouraged to message these accounts directly for source information, while also receiving promotional offers.

Thriving Commerce on Social Networks

Additionally, a robust trade exists on Telegram, where communities with numerous of participants share “before and after” photos, injection guides and claims of rapid UK delivery. Sellers market the substance there before directing buyers to WhatsApp for purchases.

Learning About The Experimental Drug

This medication is an investigational injectable created by US drugmaker Eli Lilly. The drug affects three intestinal hormones – glucagon-like peptide-1, GIP and glucagon. Preliminary studies indicate it could help patients reduce up to a quarter of their body weight. Nicknamed the “triple G”, the drug is being promoted online as the next Ozempic.

Medical Professionals Express Worries

However, physicians and pharmacists have warned that the distribution of what is still an unapproved drug in the UK is worrisome and could result in users injecting products of unknown origin.

Some experts said the popularity for the experimental drug could be connected to the increasing price of approved weight loss treatments such as Mounjaro.

Legal Position and Implementation

Selling the unapproved drug on social media or messaging apps is illegal in the United Kingdom, as it is an unapproved medication that cannot be marketed or supplied for personal consumption under the Human Medicines Regulations 2012.

Several influencers try to circumvent the rules by calling to the substance as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a controlled drug, but promotion and supply can still breach medicines, advertising, and consumer regulations, risking penalties, legal action or prison.

Platform Response and Material Elimination

Based on the social media company, the service has taken down problematic material and banned associated hashtags and query recommendations. The organization stated it was committed to keeping the platform safe and investing in strengthening enforcement strategies.

Digital Trading Activities

Investigations also discovered groups with up to 9,000 participants selling retatrutide using Telegram's built-in search feature, which functions like a public directory. Typing “retatrutide” immediately displays channels with thousands of users, filled with images of weight loss, positive testimonials and step-by-step instructions for preparing or injecting at home.

Within moments of joining one group, a seller shared contact information, where most purchases occur. The seller sent an guidebook and guaranteed delivery within two days. When asked whether the substance was authentic, one vendor said: “You can’t be sure.” Another provided a photo of a supposed laboratory certificate. None asked about weight, medical conditions or previous experience.

Product Details and Pricing

Within these groups, messages show black plastic packages with postal service stickers, stating to include new batches. One message stated: “It took eight of us to load them this morning.”

Customers can choose between powder vials, prepared at home with purified liquid, or pre-filled injectors usually priced at £160 for 20 milligrams. When asked how long a pen should be used, vendors give contradictory answers varying between a several days to “depends on your body”.

Service Oversight and Security Measures

A spokesperson for Telegram stated it actively moderated dangerous content on its service including material that encouraged the “misuse of controlled medications”. The organization noted that it removed “millions of pieces of harmful content each day”.

Medical Expert Warnings

“People are administering substances they can’t verify. Even if the science behind this drug is valid, these digital products may not include what they claim,” said a pharmacy expert, the director of pharmacy at a pharmacy service.

A medical professional of an online medical service linked the surge in demand to current cost increases for approved weight-loss drugs such as Mounjaro. “With costs rising, patients are using online platforms. But counterfeit injections are extremely risky. You cannot know what’s contained or whether the conditions they were produced in was sterile,” she explained.

Her staff has previously seen patients injured by self-injection from unconfirmed suppliers. “We understand the frustration, but purchasing from Telegram or communication platforms is taking chances with your well-being,” said the doctor. “These materials could be impure or improperly measured.”

Manufacturer Statement

A representative from the pharmaceutical company said retatrutide was in third stage research studies and had not been evaluated or approved by any government authority globally. “Therefore at this point no one can market [it] for human use,” they explained, noting that any product “falsely representing itself as a Lilly investigational substance not yet approved … may subject users to possibly serious health risks”.